Navigation Links
Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
Date:1/22/2013

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. In November 2012, Omeros announced that OMS302 met the co-primary efficacy endpoints in this second pivotal Phase 3 clinical trial by demonstrating statistically significant (p<0.00001) maintenance of intraoperative mydriasis (pupil dilation) and statistically significant (p=0.0002) reduction of pain in the early postoperative period.

This multicenter, double-blind, Phase 3 clinical trial enrolled 416 patients randomized 1:1 to receive either OMS302 or placebo. Safety data were collected through postoperative day 90. In this Phase 3 clinical trial, OMS302 was well tolerated. The incidence of adverse events was similar between the two treatment groups, and the adverse event profile was similar to that seen in prior OMS302 clinical trials. No safety concerns have been identified in the OMS302 clinical development program. Results from this study are expected to be presented at an upcoming major ophthalmology meeting. Omeros also plans to publish the results in a leading peer-reviewed ophthalmology journal.

"While these data were expected, they underscore the safety benefits of intraoperative and local delivery of OMS302 – administration of efficacious and low concentrations of the active ingredients directly to the surgical site reduces systemic uptake an
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
2. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
3. Omeros is Not Aware of Any Justification for Share Price Movement
4. Omeros Corporation Reports Third Quarter 2012 Financial Results
5. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
6. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
7. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
8. Omeros to Present at Two Upcoming Conferences
9. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
10. Omeros Corporation Reports Second Quarter 2012 Financial Results
11. Omeros Announces Discovery in MASP-2 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider ... the Life Sciences sector, by setting up Intelent ... 3 million USD . Intelent aims to address the ... projections by McKinsey) by providing clients offerings in the areas ... Noting the exponential growth in ...
(Date:7/29/2015)... -- Touro College has announced that it is supporting ... five media marijuana licenses to be issued by the ... If CanniCare is selected, Touro would provide ... "Our college is supportive of medicinal development and research," said ... System. "There is still a great deal of research to ...
(Date:7/29/2015)... 2015  Cepheid (Nasdaq: CPHD ) today ... Xpert® Carba-R, with the addition of two newly ... molecular test also detects and differentiates among the ... KPC, NDM, VIM, IMP-1 and OXA-48. ... Superbugs, are a growing and expensive challenge for ...
Breaking Medicine Technology:TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 2TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 3Touro College Announces Support for CanniCare's Medical Cannabis License Application 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4
... 3, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect ... principal amount of senior unsecured notes (the "Notes"). ... Securities Act of 1933, as amended (the "Securities Act"), ...
... Feb. 3, 2011 Unilife Corporation ("Unilife" or the "Company") ... it has appointed Dr. Ramin Mojdeh, formerly Vice President and ... and Worldwide Vice President of Research and Development, BD Medical, ... effective February 7, 2011. Dr. Mojdeh comes ...
Cached Medicine Technology:Valeant Launches Senior Notes Offering 2Valeant Launches Senior Notes Offering 3Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 2Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 3Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 4Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 5
(Date:7/29/2015)... ... July 29, 2015 , ... On ... regulations imposed by the FDA for nicotine laced liquid products. Their report says ... have raised considerably. E-Cigarettes are particularly troublesome to addiction professionals as many of ...
(Date:7/29/2015)... ... July 29, 2015 , ... Orthopedic surgeons at Lourdes Medical ... Rotation Medical Rotator Cuff System, a new implant to treat a common source of ... foster natural regeneration of additional tendon tissue, which could allow for faster healing and ...
(Date:7/29/2015)... , ... July 29, 2015 , ... CanAm Enterprises, LLC ... USCIS over the past month! I-829 approvals have been granted to investors in four ... Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center ...
(Date:7/29/2015)... ... ... It is unique for a health center to dedicate a full-time medical ... is very hands on and resident oriented, and one to which Dr. Rennecker is ... and energy, as well as a strong commitment to helping seniors live longer, healthier ...
(Date:7/29/2015)... ... , ... Attorneys representing American families in national talcum powder lawsuits announce the ... a page dedicated to news related to pending talcum powder lawsuits, as well as ... News page was launched with eight initial articles. , “We decided to add ...
Breaking Medicine News(10 mins):Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 3
... insulin resistance and high blood pressure begin as early ... measured obesity, insulin resistance, blood pressure and cholesterol levels ... the young people were 13 and again when they ... mass index (BMI) calculation. BMI is the person's weight ...
... is being tested against cervical cancer. Human papilloma virus ... but not everyone with the virus develops the cancer. ... and causes 300,000 deaths. If it is diagnosed and ... survival rate. // ,Doctors at Britain's Cancer ...
... body to the ageing process and may increase the ... and diabetes, researchers have found. ,These days, the average ... more developed countries has decreased from nine hours to ... increased demands of work and more leisure activities. ...
... who work nightshifts are more prone to develop breast cancer. ... worked during the nights for up to three years were ... did not work at night. ,And the risk increased to ... three years. ,The results of the study, carried ...
... Women who have irregular or very long menstrual cycles ... such menstrual abnormalities needn't panic because the risk can ... exercise and weight control. // ,Menstrual cycles ... be markers for some sort of underlying metabolic abnormality. ...
... study, cycling has shown a beneficial effect in treating sexual ... produce sexual dysfunction in men because blood flow is restricted, ... an erection. The problem is that many of these men ... medication for heart failure. ,Researchers in France reported ...
Cached Medicine News:Health News:Heart disease starts early 2Health News:Deprived sleep leads to ageing 2
... System is a latex-free unisex system ... simple catheterization designed to reduce the ... It includes a 100% latex-free Mentor ... tear tab makes it easy to ...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: